<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00444873</url>
  </required_header>
  <id_info>
    <org_study_id>A-94-52030-163</org_study_id>
    <secondary_id>2004-001435-33</secondary_id>
    <nct_id>NCT00444873</nct_id>
  </id_info>
  <brief_title>Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With Acromegaly</brief_title>
  <official_title>A Phase III, Multicentre, Open Label, Comparative, Dose-interval Titration Study Evaluating the Efficacy and Safety of Six Repeated Deep Subcutaneous Administrations of Lanreotide Autogel 120mg, in Acromegalic Patients Previously Treated With Octreotide LAR</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ipsen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ipsen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicentre, prospective, open label study of acromegalic patients evaluating the efficacy&#xD;
      and safety of different dose-intervals of Lanreotide Autogel 120mg according to international&#xD;
      standards and compared to previous treatment with Octreotide LAR 10, 20 or 30 mg.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Six repeated applications of Lanreotide Autogel 120mg administered every 28, 42 or 56 days.&#xD;
      For the first three injections, the interval depends on the Octreotide LAR dosage&#xD;
      administered previously. The dose interval is titrated after injection 3 depending on the&#xD;
      efficacy of the therapy with Lanreotide Autogel&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Insulin like Growth Factor 1 (IGF-1) and Growth Hormone (GH) levels at the beginning and end of the study and as proportion of patients conforming to internationally accepted levels.</measure>
    <time_frame>1 dose interval after the last administration of Lanreotide Autogel 120mg</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dose interval, 28, 42 or 56 days for repeated injections of Lanreotide Autogel 120mg which are effective in reducing IGF-1 and GH levels to internationally accepted levels.</measure>
    <time_frame>Last three injections of Lanreotiude Autogel 120mg</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose interval, 28, 42 or 56 days for repeated injections of Lanreotide Autogel 120mg, which shows comparable efficacy to the previous treatment with Octreotide LAR 10, 20 or 30 mg in controlling IGF-1 and GH levels</measure>
    <time_frame>Interval between doses after titration in part 2 of treatment (injections 3-6)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient symptoms and quality of life on Lanreotide Autogel and comparison to previous Octreotide LAR treatment.</measure>
    <time_frame>1 dose interval after the last administration of Lanreotide Autogel 120mg</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Acromegaly</condition>
  <arm_group>
    <arm_group_label>28 day dose interval</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>42 day dose interval</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>56 day dose interval</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lanreotide (Autogel formulation), duration of treatment 24-56 weeks, depending on dose interval</intervention_name>
    <description>Six deep subcutaneous injections of Lanreotide Autogel, 24-56 week intervals.</description>
    <arm_group_label>28 day dose interval</arm_group_label>
    <arm_group_label>42 day dose interval</arm_group_label>
    <arm_group_label>56 day dose interval</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The patient must give written (personally signed and dated) informed consent before&#xD;
             completing any study-related procedure.&#xD;
&#xD;
          -  The patient must have a documented diagnosis of active acromegaly and be adequately&#xD;
             treated with a stable dose (10, 20 or 30 mg) of Octreotide LAR for at least 6 months&#xD;
             immediately prior to study entry. A documented diagnosis of active acromegaly is&#xD;
             defined as IGF-1 more than 30% higher than two Standard Deviations ( +2 SD) above the&#xD;
             normal age and sex adjusted value (see Appendix 6) or GH level after OGTT (Oral&#xD;
             Glucose Tolerance Test) &gt; 2ng/mL while not under drug treatment for acromegaly. For&#xD;
             patients having undergone surgery or radiotherapy, this diagnosis must have been&#xD;
             performed after the most recent surgical or radiation treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The patient has had pituitary surgery (adenomectomy) within 6 months prior to study&#xD;
             entry&#xD;
&#xD;
          -  The patient has received stereotactic (LINAC, Gamma Knife) radiotherapy for acromegaly&#xD;
             within three years or conventional radiotherapy for acromegaly within five years prior&#xD;
             to study entry&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ipsen Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Ipsen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinikum Innenstadt</name>
      <address>
        <city>Munich</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>Schopohl J, Strasburger CJ, Caird D, Badenhoop K, Beuschlein F, Droste M, Plöckinger U, Petersenn S; German Lanreotide Study Group. Efficacy and acceptability of lanreotide Autogel® 120 mg at different dose intervals in patients with acromegaly previously treated with octreotide LAR. Exp Clin Endocrinol Diabetes. 2011 Mar;119(3):156-62. doi: 10.1055/s-0030-1267244. Epub 2010 Nov 17.</citation>
    <PMID>21086246</PMID>
  </results_reference>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>March 7, 2007</study_first_submitted>
  <study_first_submitted_qc>March 7, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2007</study_first_posted>
  <last_update_submitted>November 21, 2019</last_update_submitted>
  <last_update_submitted_qc>November 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Inappropriate Growth Hormone Secretion Syndrome (Acromegaly)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acromegaly</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lanreotide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

